Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 8c, provides guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of $0.08, $0.08 better than the analyst estimate of $0.00. Revenue for the quarter came in at $86 million versus the consensus estimate of $79.85 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2024 revenue of $320-330 million, versus the consensus of $296.7 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c